Velan Capital, L.P., one of the largest stockholders of Progenics Pharmaceuticals, Inc., announced that it has delivered a letter to stockholders expressing its concerns with the latest decision of the Progenics Board of Directors to further dilute stockholders, and providing clarity on certain misleading statements made by the Board.
- Oops, They Did it Again - Last Week the Board Chose to Further Dilute Stockholders, Proving Toxic Misalignment of Interests
- Sets the Record Straight on the Board’s Misleading Statements
- Reminds Stockholders to Follow Velan Capital, a True “Fellow Shareholder”, and Vote the GREEN Proxy Card Today AGAINST the Re-election of Peter Crowley and Michael Kishbauch
ALPHARETTA, Ga., June 11, 2019 /PRNewswire/ -- Velan Capital, L.P. (together with the other participants in its solicitation, “Velan” or “we”), one of the largest stockholders of Progenics Pharmaceuticals, Inc. (“Progenics”)(NASDAQ: PGNX), announced today that it has delivered a letter to stockholders expressing its concerns with the latest decision of the Progenics Board of Directors (the “Board”) to further dilute stockholders, and providing clarity on certain misleading statements made by the Board.
Velan’s letter can be found here: https://www.savepgnx.com/api/v1/files/60f884e8-d60f-4321-a078-08d6e8d5b29b
In the letter, Velan calls out the Board for its decision last week to dilute stockholders again by issuing equity. The Board issued 1.63 million shares of Progenics common stock at approximately $4.20 per share for a milestone payment associated with its acquisition of AZEDRA. The Board chose to issue this dilutive equity rather than make this payment from its ample balance sheet cash reserves of ~$110 million. Given the circumstances, Velan sees no rational reason to issue costly and undervalued equity.
This situation is simple. The Board does not have stockholders’ best interests at heart. Peter Crowley and Michael Kishbauch, the sole members of the Compensation Committee, own ZERO shares of common stock (excluding shares underlying options) and support flawed corporate goals, which we believe incentivizes the dilution of stockholders for the personal gain of executives and directors.
Change must occur to have true accountability and alignment with stockholders. We urge stockholders to vote AGAINST the re-election of Messrs. Crowley and Kishbauch on the GREEN proxy card.
No dilution without representation!
Investor contacts:
Deepak Sarpangal
(415) 677-7050
campaign@velancapital.com
www.SavePGNX.com
Okapi Partners LLC
Pat McHugh / Jason Alexander
(212) 297-0720
info@okapipartners.com
View original content:SOURCE Velan Capital, L.P.
Company Codes: NASDAQ-NMS:PGNX
